Results of Operations and Financial Condition. On August 6, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and six months ended June 30, 2026. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Entry into a Material Definitive Agreement Merger Agreement On August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaware limited liability company (“ Parent ”), and Coco Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), pursuant to which, subject to the terms and conditions…

Other Events. In light of the transactions contemplated by the Merger Agreement, the Company has determined to pause its previously-disclosed CEO search process. Additional Information and Where to Find It In connection with the proposed acquisition of the Company by Parent, the Company intends to file a preliminary and definitive proxy statement. The definitive proxy statement and proxy card will be delivered to the stockholders of the Company in advance of the special meeting relating to th…

The filing details transaction bonuses and amended severance agreements for certain executive officers in connection with a proposed merger.

Results of Operations and Financial Condition. On May 7, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three months ended March 31, 2026. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…

Material Modifications to Rights of Security Holders. The information set forth in

The filing details changes to the equity incentive plan and does not involve any management or director movement.

Results of Operations and Financial Condition. On February 26, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and twelve months ended December 31, 2025. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

CEO — Brian Markison: The CEO is retiring with a structured transition plan including a consulting agreement, indicating an orderly succession rather than a sudden loss.

CEO — Brian Markison: The CEO is retiring with a named internal successor (Mary Anne Heino) appointed as Interim CEO, representing an orderly succession rather than a sudden loss of leadership.

Results of Operations and Financial Condition. On November 6, 2025, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and nine months ended September 30, 2025. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…

Chief Commercial Officer — Amanda Morgan: The Chief Commercial Officer is taking a leave of absence for personal reasons, which constitutes a temporary departure of a senior executive but is not a permanent termination or resignation.

Other Events. On August 6, 2025, the Company announced that its board of directors has authorized a program to repurchase up to $400.0 million of shares of its common stock through December 31, 2027 (the “2025 Program”). The 2025 Program replaces the Company’s existing repurchase program, which was announced in November 2024. Repurchases under the 2025 Program may be made from time to time through open market transactions at prevailing market prices, in privately negotiated transactions and/o…

Results of Operations and Financial Condition. On August 6, 2025, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and six months ended June 30, 2025. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Completion of Acquisition or Disposition of Assets. As previously announced by Lantheus Holdings, Inc. (“ Lantheus ” or the “ Company ”) on January 12, 2025, Lantheus Medical Imaging, Inc., a Delaware corporation and a subsidiary of the Company, and Lantheus Radiopharmaceuticals UK Limited, a private limited liability company incorporated under the laws of England (the “ Purchaser ”), entered into a Sale and Purchase Agreement (the “ Agreement ”) with Life Medical Group Limited, a private lim…

Results of Operations and Financial Condition. On May 7, 2025 , Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three months ended March 31, 2025. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (…

Regulation FD Disclosure On April 1, 2025, Lantheus issued a press release announcing the closing of the Merger. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the…

Completion of Acquisition or Disposition of Assets. On April 1, 2025, Lantheus Medical Imaging, Inc., a Delaware corporation (“ Lantheus Medical ”) and wholly owned subsidiary of Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), completed its previously announced acquisition of Evergreen Theragnostics, Inc., a Delaware corporation (“ Evergreen ”), by means of a statutory merger of Project Hazel Merger Sub, Inc., a Delaware corporation and wholly owned subsidia…

Results of Operations and Financial Condition. On February 26, 2025 , Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three and twelve months ended December 31, 2024. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…

Director — Phuong Khanh (P.K.) Morrow, M.D.: The filing discloses the appointment of a new independent director to the board, which is a routine governance event and not a departure of a senior executive.

Regulation FD Disclosure Lantheus announced a conference call to be held at 8:30 a.m., Eastern Time on January 28, 2025. A copy of the investor presentation, which will be discussed during the conference call, is furnished as Exhibit 99.2 hereto. The information furnished pursuant to this Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section and shall not be deemed to be incorpo…

Entry into a Material Definitive Agreement. On January 27, 2025, Lantheus Medical Imaging, Inc., a Delaware corporation (“ Lantheus Medical ”) and wholly-owned subsidiary of Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), and Project Hazel Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Lantheus Medical (“ Merger Sub ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Evergreen Theragnostics, Inc., a Delaw…

Results of Operations and Financial Condition On January 28, 2025, Lantheus issued a press release announcing the signing of the Merger Agreement and reaffirming financial guidance for the year ended December 31, 2024 as set forth in the Company’s press release dated November 6, 2024. A copy of the press release is furnished as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Ex…

Entry into a Material Definitive Agreement. Sale and Purchase Agreement On January 12, 2025, Lantheus Medical Imaging, Inc., a Delaware corporation (“ Lantheus Medical ”), a subsidiary of Lantheus Holdings, Inc. (“ Lantheus ” or the “ Company ”), and Lantheus Radiopharmaceuticals UK Limited, a private limited liability company incorporated under the laws of England (the “ Purchaser ”), entered into a Sale and Purchase Agreement (the “ Agreement ”) with Life Medical Group Limited, a private li…

Regulation FD Disclosure. On January 13, 2025, the Company issued a press release announcing the signing of the Agreement. A copy of the press release is furnished as Exhibit 99.1 hereto. A copy of the Company’s investor presentation relating to the Transaction is furnished as Exhibit 99.2 hereto. The information in this item and Exhibits 99.1 and 99.2 are not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), nor shall t…